AI-generated from publicly available materials.Lantern Pharma recently conducted a webinar to showcase its innovative Open-Medicine AI multi-agentic platform aimed at enhancing drug development processes.
The live event took place on September 23, 2026, and focused on the capabilities and applications of the Open-Medicine AI platform. This platform is designed to facilitate the integration of multiple agents in drug development, potentially streamlining the process and improving outcomes. For those unable to attend, a recorded version of the webinar is accessible on YouTube and through the Investors section of Lantern Pharma's official website.
Additionally, the presentation materials from the webinar have been submitted as Exhibit 99.1 to the company's Form 8-K filing, ensuring transparency and providing stakeholders with detailed insights into the discussion.
This initiative underscores Lantern Pharma's commitment to leveraging artificial intelligence in the life sciences, positioning itself at the forefront of technological advancements in drug development. As the industry increasingly turns to AI-driven solutions, the implications for efficiency and innovation in creating new therapies could be substantial.